Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14206376 | 0.82 | CHEK1 (0.60) | CHEK1PIM1PIM3PIM2 | |
| SCHEMBL12899858 | 0.82 | PIM1 (0.47) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL19311924 | 0.81 | PIM1 (0.36) | PIM1PIM3PIM2 | |
| SCHEMBL14207423 | 0.79 | PIM1 (0.56) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL14206744 | 0.78 | CHEK1 (0.58) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886272 | 0.76 | CHEK1 (0.58) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL14038952 | 0.76 | CHEK1 (0.51) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL11886249 | 0.74 | CHEK1 (0.66) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL12899919 | 0.74 | PIM1 (0.48) | CHEK1PIM1PIM3PIM2PRKCA | |
| SCHEMBL14207411 | 0.73 | CHEK1 (0.75) | CHEK1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225235-B1 | THIAZOLE CARBOXAMIDE DERIVATIVES AND THEIR USE TO TREAT CANCER | MERCK SHARP & DOHME (US) | 2017-09-06 | — | — | EP | disclosed |
| US-8394960-B2 | Thiazole carboxamide derivatives and their use to treat cancer | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394960-B2 | Thiazole carboxamide derivatives and their use to treat cancer | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110044940-A1 | Thiazole Carboxamide Derivatives and Their Use to Treat Cancer | SCHERING CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110044940-A1 | Thiazole Carboxamide Derivatives and Their Use to Treat Cancer | SCHERING CORPORATION | 2011-02-24 | — | — | US | disclosed |
| WO-2009058729-A2 | THIAZOLE CARBOXAMIDE DERIVATIVES AND THEIR TO TREAT CANCER | SCHERING CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044940-A1 | Thiazole Carboxamide Derivatives and Their Use to Treat Cancer | LCK, TEC, MTOR | CHEK1 186/4885PIM1 1181/4885PIM3 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.